Navigation Links
Oxygen Biotherapeutics, Inc. Expands Board of Directors

DURHAM, N.C., Dec. 14 /PRNewswire-FirstCall/ -- Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBT) today announced the expansion of the company's board of directors with the addition of Lt. Gen. Ronald R. Blanck, DO, U.S. Army (Ret.). Dr. Blanck is chairman of Martin, Blanck & Associates, a federal health services consulting firm based in Falls Church, Virginia. With his addition, the company board now has nine members.

Dr. Blanck began his military career in 1968 as a medical officer and battalion surgeon in Vietnam. He retired 32 years later as a Lieutenant General and Surgeon General of the U.S. Army and commander of the U.S. Army Medical Command with more than 46,000 military personnel and 26,000 civilian employees throughout the world. During his distinguished military career, Dr. Blanck also served as commander of Walter Reed Medical Center and the North Atlantic Region Medical Command.

After his military service and prior to joining Martin, Blanck & Associates, Dr. Blanck served as the president of the University of North Texas Health Science Center at Fort Worth. As president, Dr. Blanck headed a growing academic health center that includes the Texas College of Osteopathic Medicine, Graduate School of Biomedical Sciences, School of Public Health and School of Health Professions.

"I am very honored that an individual with Ron Blanck's combination of military and medical credentials is coming onto our board of directors, especially as we look toward expanding our efforts in Defense Medicine(TM). As you know, we believe Oxycyte(TM) has the potential to help reduce the long-term brain damage to our forces who are blast injury casualties in Iraq and Afghanistan. His medical expertise and his military contacts should be helpful in our efforts in this area," said Chris Stern, company chairman and CEO.

"Also, this expansion of the board is part of our goal to change the board's structure so that it builds out its majority of independent outside directors, something I believe is important in view to a move to a major exchange listing," said Stern.

About Oxygen Biotherapeutics, Inc.

Oxygen Biotherapeutics, Inc. is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and Defense Medicine(TM). The company has developed a perfluorocarbon (PFC) therapeutic oxygen carrier and liquid ventilation product (Oxycyte(TM)) and has out-licensed an implantable glucose sensor. These products are based upon core technologies that include biomedical applications for PFCs as well as medical and industrial applications for biosensors. Each of the product candidates is designed with advantages over currently marketed products in major markets including traumatic brain injury, sickle cell crisis, trauma, wound care, decompression sickness, acute respiratory distress syndrome, stroke, myocardial infarction, surgery, diabetes wounds and ulcers, and cosmetic applications which are being marketed under the Dermacyte name. More information is available at

SOURCE Oxygen Biotherapeutics, Inc.

SOURCE Oxygen Biotherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Sangart, Inc. Initiates Phase IIa Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock
2. Oxygen Biotherapeutics, Inc. Enrolls First Patient in Traumatic Brain Injury Clinical Trial in Switzerland
3. Reportlinker Adds Medical Oxygen Systems - Global Market Opportunities
4. Oxygen Biotherapeutics, Inc. Begins Shipping Cosmetic Product to Customers
5. Oxygen Biotherapeutics, Inc. Announces 1:15 Reverse Stock Split to Take Effect Nov. 9, 2009
6. Oxygen Biotherapeutics, Inc. to Webcast Shareholder Meeting
7. Oxygen Biotherapeutics, Inc. Receives Phase II Trial Approval in Israel
8. Oxygen Biotherapeutics, Inc. Submits Milestone Achievement Notice to Vatea Fund
9. New NIH-Funded Study Shows Masimo Rainbow SET(R) May Help Clinicians Assess Oxygenation in Children With Sickle Cell Disease
10. Oxygen Biotherapeutics, Inc. Receives Letter From FDA Outlining Path Forward to Resume Oxycyte Clinical Trials in TBI in U.S.A.
11. Battelle Scientists Named on Patent for Making Oxygen From Light and Water
Post Your Comments:
(Date:11/30/2015)... and SAN DIEGO , Nov. ... Inc. (NASDAQ: ARNA ) today announced that the ... filing the New Drug Application (NDA) for an extended ... formulation will offer patients a chronic weight management treatment ... ) is currently approved as an adjunct to a ...
(Date:11/30/2015)... ST. LOUIS , Nov. 30, 2015  Premera ... today announced an early renewal of the companies, long-standing ... will now extend through at least 2019. ... pharmacy benefit manager capabilities during a competitive review and ... offer the best health plan integration and deliver the ...
(Date:11/30/2015)... N.H. , Nov. 30, 2015 ... that it will feature its latest solutions for ... early identification of cancer at the Radiological Society ... Chicago from November 29 ... recent product advances including iReveal®, an automated breast ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... ... The successful filing of an Investigational New Drug application (IND) is a ... key industry segment, Regis Technologies has decided to sponsor and participate in an XTalks-hosted ... , Federal law does not allow new drugs to cross state lines until it ...
(Date:11/30/2015)... ... November 30, 2015 , ... SIMmersion’s ability to present dynamic ... schools of the future. To reach an audience of key visionaries and reformers ... in Chicago, organized by the American Medical Association. , AMA President Steven ...
(Date:11/30/2015)... (PRWEB) , ... November 30, ... ... Service, Inc. are pleased to announce their strategic partnership at the Radiological ... Keystrokes Transcription Service, Inc., and Winscribe, global providers of cutting-edge dictation and ...
(Date:11/30/2015)... ... ... today announced the introduction of three Nightstick® brand LED traffic wands with an average retail ... NSP-1632 ), yellow ( NSP-1634 ) and blue ( NSP-1636 ), the SL-1600 series LED ... in blinking strobe mode using a fresh set of 3 AAA cells (included). , Built ...
(Date:11/29/2015)... ... ... The Cyber Monday deal is a deep 40% or more discount on every item on ... the skin care lover in your circle. Each Christmas, Sublime Beauty offers a special ... serums are staples: Collagen, Retinol and Hyaluronic Serums. , Stocking stuffers like Skin Brushes, natural ...
Breaking Medicine News(10 mins):